BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We investigated B-cell lymphoma 2 (BCL2) regulation across DNA, RNA, protein, and methylation status according to molecular subtype of breast cancer using The Cancer Genome Atlas (TCGA) database. Materials and Methods We analyzed clinical and biological data on 1,096 breast cancers from the TCGA database. Biological data included reverse phase protein array (RPPA), mRNA sequencing (mRNA-seq), mRNA microarray, methylation, copy number alteration linear, copy number alteration nonlinear, and mutation data. Results The luminal A and luminal B subtypes showed upregulated expression of RPPA and mRNAseq and hypomethylation compared to the human epidermal growth factor receptor 2 (HER2) and triple-negative subtypes (all p < 0.001). No mutations were found in any subjects. High mRNA-seq and high RPPA were strongly associated with positive estrogen receptor, positive progesterone receptor (all p < 0.001), and negative HER2 (p < 0.001 and p=0.002, respectively). Correlation analysis revealed a strong positive correlation between protein and mRNA levels and a strong negative correlation between methylation and protein and mRNA levels (all p < 0.001). The high BCL2 group showed superior overall survival compared to the low BCL2 group (p=0.006). Conclusion The regulation of BCL2 was mainly associated with methylation across the molecular subtypes of breast cancer, and luminal A and luminal B subtypes showed upregulated expression of BCL2 protein, mRNA, and hypomethylation. Although copy number alteration may have played a minor role, mutation status was not related to BCL2 regulation. Upregulation of BCL2 was associated with superior prognosis than downregulation of BCL2.
Abstract
Purpose We investigated B-cell lymphoma 2 (BCL2) regulation across DNA, RNA, protein, and methylation status according to molecular subtype of breast cancer using The Cancer Genome Atlas (TCGA) database. Materials and Methods We analyzed clinical and biological data on 1,096 breast cancers from the TCGA database. Biological data included reverse phase protein array (RPPA), mRNA sequencing (mRNA-seq), mRNA microarray, methylation, copy number alteration linear, copy number alteration nonlinear, and mutation data. Results The luminal A and luminal B subtypes showed upregulated expression of RPPA and mRNAseq and hypomethylation compared to the human epidermal growth factor receptor 2 (HER2) and triple-negative subtypes (all p < 0.001). No mutations were found in any subjects. High mRNA-seq and high RPPA were strongly associated with positive estrogen receptor, positive progesterone receptor (all p < 0.001), and negative HER2 (p < 0.001 and p=0.002, respectively). Correlation analysis revealed a strong positive correlation between protein and mRNA levels and a strong negative correlation between methylation and protein and mRNA levels (all p < 0.001). The high BCL2 group showed superior overall survival compared to the low BCL2 group (p=0.006). Conclusion The regulation of BCL2 was mainly associated with methylation across the molecular subtypes of breast cancer, and luminal A and luminal B subtypes showed upregulated expression of BCL2 protein, mRNA, and hypomethylation. Although copy number alteration may have played a minor role, mutation status was not related to BCL2 regulation. Upregulation of BCL2 was associated with superior prognosis than downregulation of BCL2.
참고문헌 (27)
- Ebrahim AS, "Hematologic malignancies: newer strategies to counter the BCL-2 protein", J Cancer Res Clin Oncol, 142, pp.2013~2022 (2016)[DOI]
- Czabotar PE, "Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy", Nat Rev Mol Cell Biol, 15, pp.49~63 (2014)[DOI]
- Tsujimoto Y, "Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation", Science, 226, pp.1097~1099 (1984)[DOI]
- Cleary ML, "Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2", immunoglobulin transcript resulting from the t(14;18) translocation, 1986, pp.47, 19~28
- Tzifi F, "The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias", Adv Hematol, 2012, pp.524308~ (2012)
- Martin B, "Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis", Br J Cancer, 89, pp.55~64 (2003)[DOI]
- Cheng H, "Bcl-2 expression and patient survival in gastric cancer: a systematic review of the literature with meta-analysis", Med Oncol, 32, pp.389~ (2015)[DOI]
- Zhao L, "Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis", Cancer Epidemiol Biomarkers Prev, 23, pp.1047~1054 (2014)[DOI]
- Correia C, "Emerging understanding of Bcl-2 biology: implications for neoplastic progression and treatment", Biochim Biophys Acta, 1853, pp.1658~1671 (2015)[DOI]
- Delbridge AR, "Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies", Nat Rev Cancer, 16, pp.99~109 (2016)[DOI]
- Dawson SJ, "BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received", Br J Cancer, 103, pp.668~675 (2010)[DOI]
- Callagy GM, "Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer", BMC Cancer, 8, pp.153~ (2008)[DOI]
- Hwang KT, "Prognostic influence of BCL2 expression in breast cancer", Int J Cancer, 131, pp.1109~1119 (2012)[DOI]
- 황기태, "Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer", Journal of Breast Cancer, 20(1), pp.54~64 (2017), 한국유방암학회[DOI]
- Seong MK, "Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer", Breast Cancer Res Treat, 150, pp.141~148 (2015)[DOI]
- McDonnell TJ, "Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18)", Nature, 349, pp.254~256 (1991)[DOI]
- Cancer Genome Atlas Research Network, "The Cancer Genome Atlas Pan-Cancer analysis project", Nat Genet, 45, pp.1113~1120 (2013)[DOI]
- Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)[DOI]
- Ciriello G, "Comprehensive molecular portraits of invasive lobular breast cancer", Cell, 163, pp.506~519 (2015)[DOI]
- Chang JT, "Identification of microRNAs as breast cancer prognosis markers through The Cancer Genome Atlas", PLoS One, 11, pp.e0168284~ (2016)[DOI]
- Ma CX, "The Cancer Genome Atlas: clinical applications for breast cancer", Oncology (Williston Park), 27, pp.1263~1269 (2013)
- Bouchalova K, "Triple negative breast cancer: BCL2 in prognosis and prediction. Review", Curr Drug Targets, 15, pp.1166~1175 (2014)[DOI]
- Park SH, "Down regulation of bcl2 expression in invasive ductal carcinomas is both estrogen- and progesterone-receptor dependent and associated with poor prognostic factors", Pathol Oncol Res, 8, pp.26~30 (2002)[DOI]
- Bhargava V, "Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity", Am J Pathol, 145, pp.535~540 (1994)
- Doglioni C, "The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status", Virchows Arch, 424, pp.47~51 (1994)
- Chen LY, "Bcl2 and Ki67 refine prognostication in luminal breast cancers", Breast Cancer Res Treat, 149, pp.631~643 (2015)[DOI]
- Lee KH, "Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy", BMC Cancer, 7, pp.63~ (2007)[DOI]